Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma

Published:2021-09-27 Issue:5 Volume:74 Page:2652-2669
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Torrens Laura¹²^ORCID,Montironi Carla¹²^ORCID,Puigvehí Marc¹³^ORCID,Mesropian Agavni²^ORCID,Leslie Jack⁴^ORCID,Haber Philipp K.¹,Maeda Miho¹,Balaseviciute Ugne²^ORCID,Willoughby Catherine E.²^ORCID,Abril‐Fornaguera Jordi²^ORCID,Piqué‐Gili Marta²^ORCID,Torres‐Martín Miguel¹²^ORCID,Peix Judit²^ORCID,Geh Daniel⁴^ORCID,Ramon‐Gil Erik⁴^ORCID,Saberi Behnam¹,Friedman Scott L.¹^ORCID,Mann Derek A.⁴^ORCID,Sia Daniela¹^ORCID,Llovet Josep M.¹²⁵^ORCID

Affiliation:

1. Mount Sinai Liver Cancer Program Division of Liver Diseases Tisch Cancer InstituteIcahn School of Medicine at Mount Sinai New York NY

2. Translational Research in Hepatic Oncology Liver Unit Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)‐Hospital ClínicUniversitat De Barcelona Barcelona Spain

3. Hepatology Section Gastroenterology Department Parc de Salut MarIMIM (Hospital del Mar Medical Research Institute) Barcelona Spain

4. Newcastle Fibrosis Research Group Biosciences InstituteNewcastle University Newcastle upon Tyne United Kingdom

5. Institució Catalana De Recerca i Estudis Avançats Barcelona Spain

Funder

Cancer Research UK

Universitat de Barcelona

European Association for the Study of the Liver

Deutsche Forschungsgemeinschaft

Samuel Waxman Cancer Research Foundation

Ministerio de Ciencia e Innovación

U.S. Department of Defense

Asociación Española para el Estudio del Hígado